

Azeez Farooki

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9340018/azeez-farooki-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32
papers

1,260
citations

16
h-index

35
g-index

36
ext. papers

1,453
ext. citations

6.8
avg, IF

4.19
L-index

#	Paper	IF	Citations
32	Vertebral Fractures After Denosumab Discontinuation in Breast Cancer Survivors: A Single Institution Experience. <i>HSS Journal</i> , 2021 , 17, 185-191	2	
31	Bone Mineral Density: Clinical Relevance and Quantitative Assessment. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 446-454	8.9	2
30	Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	14
29	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. <i>Cancer</i> , 2020 , 126, 4532-4544	6.4	2
28	Pituitary as a Source of HCG: Residual Levels After Bilateral Testicular Tumor Removal. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2019 , 7, 2324709619841414	1.2	
27	Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 135-141	2	27
26	Antiresorptive agents\bone-protective and adjuvant effects in postmenopausal women with early breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1125-1135	3.8	5
25	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky021	4.6	73
24	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. <i>Journal of Bone Oncology</i> , 2017 , 7, 32-37	4.5	16
23	Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2017 , 129, 159-168	3.7	27
22	Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy. <i>Oncologist</i> , 2017 , 22, 438-444	5.7	28
21	Maintaining Bone Health During Hormonal Therapy for Prostate Cancer. <i>Annals of Internal Medicine</i> , 2017 , 167, 357-358	8	1
20	Ga-68 DOTATOC PET/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced Osteomalacia. <i>CardioVascular and Interventional Radiology</i> , 2016 , 39, 1352-7	2.7	14
19	Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016 , 44, 265-70	3.6	16
18	Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e303-309 ²¹	3.3	21
17	Denosumab and fracture risk in women with breast cancer. <i>Lancet, The</i> , 2015 , 386, 2056-2057	40	1
16	Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. <i>Endocrine-Related Cancer</i> , 2014 , 21, R247-59	5.7	39

15	Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies. <i>Endocrine</i> , 2014 , 47, 266-72	4	18
14	Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. <i>Leukemia Research</i> , 2013 , 37, 790-4	2.7	16
13	NCCN Task Force Report: Bone Health In Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11 Suppl 3, S1-50; quiz S51	7.3	136
12	Risk assessment for severe hypocalcemia requiring hospitalization with denosumab.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 115-115	2.2	1
11	Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2919-28	2.2	160
10	Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012 , 70, 2768-75	1.8	12
9	Skeletal-related events due to bone metastases from differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2433-9	5.6	81
8	Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. <i>Annals of the New York Academy of Sciences</i> , 2011 , 1218, 80-7	6.5	20
7	Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. <i>Journal of Bone and Joint Surgery - Series A</i> , 2011 , 93, 1235-42	5.6	77
6	NCCN Task Force Report: Bone Health in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7 Suppl 3, S1-32; quiz S33-5	7.3	145
5	Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. <i>Oncologist</i> , 2008 , 13, 911-20	5.7	113
4	Osteonecrosis of the jaw related to bevacizumab. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4037-8	2.2	171
3	Anabolic therapies for osteoporosis. <i>New England Journal of Medicine</i> , 2007 , 357, 2410-1	59.2	8
2	Insulin resistance and cancer-related mortality. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1628-9; author reply 1629-30	2.2	3
1	Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Bowker et Al. <i>Diabetes Care</i> , 2006 , 29, 1989-90	14.6	6